公开(公告)号：US20230183261A1

公开(公告)日：2023-06-15

申请号：US17649906

申请日：2022-02-03

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Andrew S. Judd ,  Aaron R. Kunzer ,  Chunqiu Lai ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Jesse A. Teske ,  Anthony Mastracchio ,  Xilu Wang ,  Cheng Ji ,  Michael D. Wendt ,  Xiaohong Song ,  George A. Doherty ,  Katja Jantos ,  Wilfried Braje ,  Andreas Kling ,  Frauke Pohlki ,  Thomas D. Penning

IPC: C07D495/16 ,  C07D495/18 ,  A61K45/06 ,  C07D495/22 ,  C07D491/18 ,  A61K31/519 ,  C07D491/22 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07D495/16 ,  C07D495/18 ,  A61K45/06 ,  C07D495/22 ,  C07D491/18 ,  A61K31/519 ,  C07D491/22 ,  A61P35/00 ,  A61P35/02

Abstract: The present disclosure provides for compounds of formula (I)




wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US10676485B2

公开(公告)日：2020-06-09

申请号：US15998789

申请日：2018-08-15

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Andrew S. Judd ,  Aaron R. Kunzer ,  Chunqiu Lai ,  Andrew J. Souers ,  Zhi-Fu Tao ,  Anthony Mastracchio ,  Xilu Wang ,  Cheng Ji ,  Michael D. Wendt ,  Xiaohong Song ,  George A. Doherty ,  Thomas D. Penning

IPC: A61K31/395 ,  A61P35/02 ,  C07D495/16 ,  C07D495/18 ,  A61K45/06 ,  C07D495/22 ,  C07D491/18 ,  A61K31/519 ,  C07D491/22 ,  A61P35/00

Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20250092062A1

公开(公告)日：2025-03-20

申请号：US18592020

申请日：2024-02-29

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Andrew S. Judd ,  Aaron R. Kunzer ,  Chunqiu Lai ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Jesse A. Teske ,  Anthony Mastracchio ,  Xilu Wang ,  Cheng Ji ,  Michael D. Wendt ,  Xiaohong Song ,  George A. Doherty ,  Katja Jantos ,  Wilfried Braje ,  Andreas Kling ,  Frauke Pohlki ,  Thomas D. Penning

IPC: C07D495/16 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07D491/18 ,  C07D491/22 ,  C07D495/18 ,  C07D495/22

Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20180193315A1

公开(公告)日：2018-07-12

申请号：US15907597

申请日：2018-02-28

Applicant: AbbVie Inc.

Inventor： Edward A. Kesicki ,  Arthur F. Kluge ,  Michael A. Patane ,  John H. Van Drie, JR. ,  Ce Wang ,  Maricel Torrent ,  Michael L. Curtin ,  Todd M. Hansen ,  Rick F. Clark ,  Robin R. Frey ,  Zhiqin Ji ,  Yujia Dai ,  William J. McClellan ,  Jane Gong ,  Gui-dong G. Zhu ,  Anthony Mastracchio ,  Michael R. Michaelides ,  Thomas D. Penning ,  Chunqiu C. Lai

IPC: A61K31/4184 ,  C07D403/06 ,  C07D498/10 ,  A61K31/4439 ,  A61K31/423 ,  C07D405/06 ,  C07D409/06 ,  C07D403/12 ,  C07D413/14 ,  C07D235/02 ,  C07D401/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D263/52 ,  C07D491/107 ,  C07D493/10 ,  C07D495/10 ,  C07D401/06

CPC classification number: A61K31/4184 ,  A61K31/423 ,  A61K31/4439 ,  C07D235/02 ,  C07D263/52 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D407/12 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D491/107 ,  C07D493/10 ,  C07D495/10 ,  C07D498/10

Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

公开(公告)号：US09718821B2

公开(公告)日：2017-08-01

申请号：US13773906

申请日：2013-02-22

Applicant: AbbVie Inc.

Inventor： Keith W. Woods ,  Anthony Mastracchio ,  Chunqiu Lai ,  Viraj B. Gandhi ,  Thomas D. Penning

IPC: A61K31/519 ,  C07D471/14 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D471/14 ,  A61K31/519 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

公开(公告)号：US09181246B2

公开(公告)日：2015-11-10

申请号：US14444540

申请日：2014-07-28

Applicant: AbbVie Inc.

Inventor： Thomas D. Penning ,  Keith W. Woods ,  Chunqiu Lai ,  Alan S. Florjancic ,  Yunsong Tong

IPC: A61K31/395 ,  A61K31/505 ,  A61K31/535 ,  A61K31/44 ,  C07D239/02 ,  C07D401/04 ,  C07D279/10 ,  C07D471/04

CPC classification number: C07D471/04

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中R1a，R1b，R1c，X和Y在说明书中定义。 本发明还涉及含有所述化合物的组合物，其可用于抑制诸如Cdc7的激酶和治疗诸如癌症的疾病的方法。

公开(公告)号：US20140275153A1

公开(公告)日：2014-09-18

申请号：US14207841

申请日：2014-03-13

Applicant: AbbVie Inc.

Inventor： Chunqiu Lai ,  Zhi-Fu Tao ,  Keith W. Woods ,  Thomas D. Penning ,  Andrew J. Souers ,  Anthony Mastracchio ,  Julie M. Miyashiro ,  Yunsong Tong

IPC: C07D471/04 ,  A61K31/437 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/519 ,  A61K45/06 ,  C07D487/04 ,  C07D519/00

Abstract: Disclosed are compound of Formula (Ia), wherein R1A, R1, R2, R10, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).

Abstract translation: 公开了式（Ia）的化合物，其中R 1A，R 1，R 2，R 10，J，L，T，X，Y和Z如说明书中所定义，及其药学上可接受的盐。 这些化合物可以用作治疗包括癌症在内的疾病的药剂。 还提供了包含一种或多种式（Ia）化合物的药物组合物。

公开(公告)号：US20140275027A1

公开(公告)日：2014-09-18

申请号：US14207886

申请日：2014-03-13

Applicant: AbbVie Inc.

Inventor： Jianchun Gong ,  Zhi-Fu Tao ,  Thomas D. Penning ,  Andrew J. Souers ,  Yunsong Tong ,  Guidong Zhu

IPC: C07D471/04 ,  A61K31/5377 ,  A61K31/497 ,  A61K31/437

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed are compounds of Formula (IIIa), wherein R1, R2, R3, X1, X2, X3, X4, X5, have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIIa).

Abstract translation: 公开了式（IIIa）的化合物，其中R 1，R 2，R 3，X 1，X 2，X 3，X 4，X 5具有本说明书中定义的任何值及其药学上可接受的盐。 这些化合物可以用作治疗包括癌症在内的疾病的药剂。 还提供了包含一种或多种式（IIIa）化合物的药物组合物。

公开(公告)号：US20140275011A1

公开(公告)日：2014-09-18

申请号：US14207854

申请日：2014-03-13

Applicant: AbbVie Inc.

Inventor： Anthony Mastracchio ,  Milan Bruncko ,  Chunqiu Lai ,  Julie M. Miyashiro ,  Zhi-Fu Tao ,  Keith W. Woods ,  Thomas D. Penning ,  Andrew J. Souers

IPC: C07D401/04 ,  A61K31/4545 ,  C07D405/14 ,  A61K31/4439 ,  A61K31/439 ,  C07D409/14 ,  C07D417/14 ,  A61K31/444 ,  A61K31/506 ,  C07D453/02 ,  C07D401/14 ,  A61K31/5377

CPC classification number: C07D401/04 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D453/02 ,  C07D471/04

Abstract: Disclosed are compound of Formula (Ia), wherein R2, R12, R16, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

Abstract translation: 公开了式（Ia）的化合物，其中R 2，R 12，R 16，J，Q，X，Y和Z如说明书中所定义，及其药学上可接受的盐。 这些化合物可以用作治疗包括癌症在内的疾病的药剂。 还提供了包含一种或多种式（Ia）化合物的药物组合物。

公开(公告)号：US20140213610A1

公开(公告)日：2014-07-31

申请号：US14011374

申请日：2013-08-27

Applicant: AbbVie Inc.

Inventor： Thomas D. Penning ,  Gui-Dong Zhu ,  Virajkumar B. Gandhi ,  Jianchun Gong ,  Vincent L. Giranda

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/47 ,  A61K31/497 ,  A61K31/53 ,  A61K31/535 ,  C07D491/04 ,  C07D495/04

Abstract: Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

Abstract translation: 式（I）的化合物抑制PARP酶，并且可用于治疗与PARP相关的疾病或病症。 还公开了包含式（I）化合物，包含式（I）化合物的治疗方法的药物组合物，以及抑制包含式（I）化合物的PARP酶的方法。